

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

Alkermes Pharma Ireland Ltd.  
and Alkermes, Inc.  
Petitioners,

v.

Otsuka Pharmaceutical Co., Ltd.  
Patent Owner

Patent No. 9,125,939 B2  
Issued: September 8, 2015  
Filed: August 2, 2006

Inventors: Tetsuro Kikuchi, Taro Iwamoto, Tsuyoshi Hirose

Title: CARBOSTYRIL DERIVATIVES AND MOOD STABILIZERS FOR  
TREATING MOOD DISORDERS

---

*Inter Partes* Review No. IPR2017-00287

---

**PETITIONERS' UPDATED EXHIBIT LIST**

Mail Stop PATENT BOARD  
Patent Trial and Appeal Board  
United States Patent and Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313-1450

Alkermes Ex. No.	Description
Ex. 1001	U.S. Patent 9,125,939
Ex. 1002	Declaration of Allen Frances, M.D. in Support of the Petition for Inter Partes Review of U.S. Patent No. 9,125,939
Ex. 1003	Allen Frances, M.D., <i>Curriculum Vitae</i>
Ex. 1004	Declaration of Jessie Au in Support of the Petition for Inter Partes Review of U.S. Patent No. 9,125,939
Ex. 1005	Jessie Au, <i>Curriculum Vitae</i>
Ex. 1006	Tohen et al., <i>Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy</i> , ARCH. GEN. PSYCHIATRY, v.59(1): 62-69 (2002) "Tohen"
Ex. 1007	Keck PE Jr et al., <i>Aripiprazole versus placebo in acute mania</i> , Abstracts of the 2002 Annual Meeting of the American Psychiatric Association; Philadelphia, PA. USA (2002) (New Research Abstract 314 (NR314)). "Keck"
Ex. 1008	Citrome et al., <i>Pharmacokinetics and safety of aripiprazole and concomitant mood stabilizers</i> , Abstracts of the 2002 Annual Meeting of the American Psychiatric Association; Philadelphia, PA. USA (2002) (New Research Abstract 317 (NR317)). "Citrome"
Ex. 1009	<i>American Psychiatric Association, Practice guideline for the treatment of patients with bipolar disorder (Revision)</i> , Am. J. Psychiatry, 159:4, April 2002 Supplement "Practice Guidelines 2002"
Ex. 1010	Kowatch R.A. et al., <i>The use of mood stabilizers and atypical antipsychotics in children and adolescents with bipolar disorders</i> , CNS Spectrums, 8(4): 273-280 (2003) "Kowatch"
Ex. 1011	Vieta, Eduard, et al., <i>Olanzapine as long-term adjunctive therapy in treatment-resistant bipolar disorder</i> , J. CLIN. PSYCHOPHARMACOL., v.21(5): 469-473 (2001). "Vieta"
Ex. 1012	Ketter, TA. et al., <i>Rapid efficacy of olanzapine augmentation in nonpsychotic bipolar mixed states</i> [letter], J. CLIN. PSYCHIATRY, 59:83-85. (1998)

	“Ketter”
Ex. 1013	McElroy SL, et al., <i>Olanzapine in treatment-resistant bipolar disorder</i> , J. AFFECT DISORD. 49:119-122. (1998) “McElroy”
Ex. 1014	Sachs, G.S. et al., <i>Quetiapine versus placebo as adjunct to mood stabilizer for the treatment of acute mania</i> , BIPOLAR DISORDER 4 suppl. I. 133. (2002) “Sachs I”
Ex. 1015	Yatham, Lakshmi N. et al., <i>The role of novel antipsychotics in bipolar disorder</i> , J. CLIN. PSYCHIATRY 63: 10-14 (2002) “Yatham”
Ex. 1016	Petrie, J.L. et al., <i>Aripiprazole, a new atypical antipsychotic: phase II clinical trial results</i> . EUR. NEUROPSYCHOPHARM 7 (Suppl 2):S227 (1997) “Petrie”
Ex. 1017	Goodwin, G.M., <i>Typical and atypical antipsychotics in the treatment of mania</i> , EUR. NEUROPSYCHOPHARM 11 (Suppl 3): S132 (2001) “Goodwin”
Ex. 1018	Chang, Kiki D. and Ketter, Terence A., <i>Mood stabilizer augmentation with olanzapine in acutely manic children</i> , J. CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, v:10(1): 45-49 (2000) “Chang”
Ex. 1019	Del Bello M.P. et al., <i>A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania</i> , J. AM. ACAD. CHILD ADOLESC. PSYCHIATRY, 41: 1216-1223. (2002) “Del Bello”
Ex. 1020	Tohen M. et al., <i>Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study</i> , ARCH GEN PSYCHIATRY 57(9): 841-849 (2000) “Tohen II”
Ex. 1021	Haddad P. et al., <i>Adjunctive use of olanzapine in the treatment of mania</i> , INT. J. PSYCHIATRY IN CLIN PRACTICE, v3: 213-215 (1999) “Haddad”
Ex. 1022	Excerpts from the Diagnostic and Statistical Manual of Mental Disorder-IV (DSM-IV)
Ex. 1023	Jordan, S. et al., <i>The antipsychotic aripiprazole is a potent, partial</i>

	<i>agonist at the human 5-HT1A receptor</i> , EUR. J. PHARMACOL., 441(3):137-40 (2002) “Jordan”
Ex. 1024	Miller, D.S., et al., <i>Comparative efficacy of typical and atypical antipsychotics as add-on therapy to mood stabilizers in the treatment of acute mania</i> , J CLIN PSYCHIATRY, v62:975-980 (2001) “Miller”
Ex. 1025	Carlson, G.A. et al., <i>The stages of mania. A longitudinal analysis of the manic episode</i> , ARCH. GEN. PSYCHIATRY, 28(2): 221-228 (1973) “Carlson”
Ex. 1026	<i>The Expert Consensus Guideline Series Medication Treatment of Bipolar Disorder 2000, A Postgraduate Medicine Special Report</i> , April 2000 “Expert Consensus”
Ex. 1027	Griswold et al., <i>Management of Bipolar Disorder</i> , AM. FAM. PHYSICIAN 62(6):1343-1353 (2000) “American Family Physician”
Ex. 1028	<i>Data Demonstrate Aripiprazole Significantly Improved Symptoms of Acute Mania in Patients With Bipolar Disorder; New Data Presented Today at American Psychiatric Association Annual Meeting</i> , PR Newswire, May 22, 2002, “BMS/Otsuka Press Release”
Ex. 1029	Frye et al., <i>The Increasing Use of Polypharmacotherapy for Refractory Mood Disorders: 22 Years of Study</i> , J CLIN PSYCHIATRY 61(1): 9-15 (2000) “Frye”
Ex. 1030	Zar, <i>Measures of Dispersion and Variability</i> , in <i>Biostatistical Analysis</i> , Prentice Hall (1974). (“Zar”)
Ex. 1031	Shimokawa, <i>High Performance Liquid Chromatographic Methods for the Determination of Aripiprazole with Ultraviolet Detection in Rat Plasma and Brain: Application to the Pharmacokinetic Study</i> , JOURNAL OF CHROMATOGRAPHY 21, 8-14, 13 (2005). (“Shimokawa”)
Ex. 1032	Chiu and Franklin, <i>Analysis and Pharmacokinetics of Olanzapine (LY170053) and Two Metabolites in Rat Plasma Using Reversed-Phase HPLC with Electrochemical Detection</i> , JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 14, 609-615 (1996). (“Chiu and Franklin”)
Ex. 1033	Mattiuz et al., <i>Disposition and Metabolism of Olanzapine in Mice</i> ,

	Dogs, and Rhesus Monkeys, DRUG METABOLISM AND DISPOSITION, 25: 573-583 (1997). (“Mattiuz”)
Ex. 1034	Aravagiri et al., Pharmacokinetics and Tissue Distribution of Olanzapine in Rats, BIOPHARMACEUTICS & DRUG DISPOSITION, 20: 369–377 (1999). (“Aravagiri”)
Ex. 1035	Gunaratna et al., An automated blood sampler for simultaneous sampling of systemic blood and brain microdialysates for drug absorption, distribution, metabolism, and elimination studies, JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS 49: 57-64 (2004). (“Gunaratna”)
Ex. 1036	Furukawa, Modifications by Lithium of Behavioral Responses to Methamphetamine and Tetrabenazine, PSYCHOPHARMACOLOGIA, 42, 243-248 (1975). (“Furukawa”)
Ex. 1037	Okada, Inhibition by Antimanic Drugs of Hyperactivity Induced by Methamphetamine-Chlordiazepoxide Mixture in Mice, PHARMACOLOGY BIOCHEMISTRY & BEHAVIOR, 35, 897-901 (1990). (“Okada”)
Ex. 1038	Takigawa, Intracranial Self-Stimulation and Locomotor Traces as Indicators for Evaluating and Developing Antipsychotic Drugs, JAPANESE JOURNAL OF PSYCHIATRY AND NEUROLOGY, 48, 1, 127-132 (1994). (“Takigawa”)
Ex. 1039	Ago, Lithium Attenuates Methamphetamine-Induced Hyperlocomotion and Behavioral Sensitization Via Modulation of Prefrontal Monoamine Release, NEUROPHARMACOLOGY 62, 1634-1639 (2012). (“Ago”)
Ex. 1040	Zhao et al., Comparison of Methods for Evaluating Drug-Drug Interaction, FRONTIERS IN BIOSCIENCE E2, 241-249 (2010).
Ex. 1041	Fraser, The Antagonism Between the Actions of Active Substances, THE BRITISH MEDICAL JOURNAL, 457-459 (1872). (“Fraser”)
Ex. 1042	Berenbaum, A Method for Testing for Synergy with Any Number of Agents, JOURNAL OF INFECTIOUS DISEASES, 137, 2, 122-130, (1978). (“Berenbaum”)
Ex. 1043	Chou and Talalay, Quantitative Analysis of Dose-Effect Relationships: the Combined Effects of Multiple Drugs or Enzyme Inhibitors, in ADVANCES IN ENZYME REGULATION, Vol. 22, 1983). (“Chou and Talalay”)
Ex. 1044	Greco, Application of a New Approach for the Quantitation of Drug Synergism to the Combination of cis-Diamminedichloroplatinum and 1-b-D-Arabinofuranosylcytosine,

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.